menu
    • menu

    Company profile for GV20 Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfoli...
    GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfolio of immuno-oncology antibody drug candidates for cancer treatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GV20 TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://gv20tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gv20tx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GV20 Therapeutics Presents GV20-0251 Translational Findings
    GV20 Therapeutics Presents GV20-0251 Translational Findings

    18 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-late-breaking-oral-presentation-of-gv20-0251-translational-findings-at-the-aacr-annual-meeting-2026-302713853.html

    PR NEWSWIRE
    18 Mar 2026
    Share Share
    GV20 Therapeutics Hits ADC Milestone with Mitsubishi Tanabe
    GV20 Therapeutics Hits ADC Milestone with Mitsubishi Tanabe

    25 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-achievement-of-milestone-under-antibody-drug-conjugate-collaboration-with-mitsubishi-tanabe-pharma-corporation-302625157.html

    PR NEWSWIRE
    25 Nov 2025
    Share Share
    GV20 Therapeutics to Present Ph 1 Data on GV20-0251 at ASCO 2025
    GV20 Therapeutics to Present Ph 1 Data on GV20-0251 at ASCO 2025

    23 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-updated-phase-1-monotherapy-data-on-gv20-0251-at-the-asco-annual-meeting-2025-302463357.html

    PR NEWSWIRE
    23 May 2025
    Share Share
    GV20 Therapeutics, Mitsubishi Tanabe collaborate on ADC Development
    GV20 Therapeutics, Mitsubishi Tanabe collaborate on ADC Development

    27 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-collaboration-agreement-with-mitsubishi-tanabe-pharma-corporation-to-develop-novel-antibody-drug-conjugates-302411169.html

    PR NEWSWIRE
    27 Mar 2025
    Share Share
    GV20 Therapeutics Reports Phase 1 Data On GV20-0251 At ESMO
    GV20 Therapeutics Reports Phase 1 Data On GV20-0251 At ESMO

    16 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-promising-phase-1-monotherapy-data-on-novel-checkpoint-inhibitor-gv20-0251-at-esmo-congress-2024-302247149.html

    PR NEWSWIRE
    16 Sep 2024
    Share Share
    GV20 Therapeutics To Present GV20-0251 Clinical Data At ESMO 2024
    GV20 Therapeutics To Present GV20-0251 Clinical Data At ESMO 2024

    21 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-clinical-data-on-gv20-0251-at-the-esmo-congress-2024-302225841.html

    PR NEWSWIRE
    21 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search